Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Neurotech International ( (AU:NTI) ).
Neurotech International reported a pivotal quarter marked by the US FDA granting Rare Pediatric Disease Designation to its lead drug NTI164 for Rett syndrome, adding to existing US and European Orphan Drug Designations and significantly enhancing the program’s regulatory, commercial and partnering appeal through potential access to priority review, tax incentives and extended market exclusivity. Supporting its broader paediatric neurology strategy, new clinical and mechanistic data from an open-label Phase I/II trial of NTI164 in children with PANS were published in the high-impact journal Neurotherapeutics, showing the therapy was well tolerated and delivered statistically significant improvements across key disease domains while normalising dysregulated epigenetic, ribosomal and immune pathways, thereby strengthening the scientific rationale for NTI164 across multiple neuroinflammatory paediatric indications. Financially, Neurotech bolstered its balance sheet with approximately $4 million raised via a placement backed by both new and existing investors, alongside a $4.73 million R&D tax incentive refund, funding IND-enabling toxicology, registration-focused clinical development and regulatory activities as the company advances NTI164 toward later-stage trials and positions itself for future regulatory engagement and potential partnering discussions.
The most recent analyst rating on (AU:NTI) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
More about Neurotech International
Neurotech International is a clinical-stage biopharmaceutical company focused on developing cannabinoid-based therapies for paediatric neurological and neuroimmune disorders. Its lead oral drug candidate, NTI164, is being evaluated across multiple neurodevelopmental indications, including autism spectrum disorder, Rett syndrome and PANS/PANDAS, targeting rare and underserved paediatric markets in the United States, Europe and other key jurisdictions.
Average Trading Volume: 873,947
Technical Sentiment Signal: Sell
Current Market Cap: A$20.74M
Find detailed analytics on NTI stock on TipRanks’ Stock Analysis page.